Enanta Pharmaceuticals (ENTA) EBITDA Margin Growth (5y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7,845.00 |
| Dec 31, 2025 | -2,171.00 |
| Sep 30, 2025 | -3,784.00 |
| Jun 30, 2025 | 1,935.00 |
| Mar 31, 2025 | -12,133.00 |
| Dec 31, 2024 | -16,331.00 |
| Sep 30, 2024 | -21,691.00 |
| Jun 30, 2024 | -14,304.00 |
| Mar 31, 2024 | -18,884.00 |
| Dec 31, 2023 | -23,364.00 |
| Sep 30, 2023 | -21,517.00 |
| Jun 30, 2023 | -23,387.00 |
| Mar 31, 2023 | -25,997.00 |
| Dec 31, 2022 | -16,498.00 |
| Sep 30, 2022 | -20,464.00 |
| Jun 30, 2022 | 775.00 |
| Mar 31, 2022 | -7,474.00 |
| Dec 31, 2021 | -4,235.00 |
| Sep 30, 2021 | -11,893.00 |
| Jun 30, 2021 | -14,873.00 |
| Mar 31, 2021 | -14,318.00 |
| Dec 31, 2020 | -11,222.00 |
| Sep 30, 2020 | -10,920.00 |
| Jun 30, 2020 | -13,719.00 |
| Mar 31, 2020 | -12,765.00 |
| Dec 31, 2019 | -6,611.00 |
| Sep 30, 2019 | 21,450.00 |
| Jun 30, 2019 | -7,452.00 |
| Mar 31, 2019 | 23,407.00 |
| Dec 31, 2018 | 65,095.00 |
| Sep 30, 2018 | 39,974.00 |
| Jun 30, 2018 | 29,290.00 |
| Mar 31, 2018 | 37,281.00 |
| Dec 31, 2017 | -4,092.00 |
| Sep 30, 2017 | 29,196.00 |
| Jun 30, 2017 | -3,601.00 |
| Mar 31, 2017 | -19,388.00 |